Zydus Cadila in talks to sell two units for around Rs 1,200 crIllustrative image – not actual.
Zydus Cadila is in preliminary talks with several strategic and private equity investors to sell two of its divisions--anti-infectives and gynaecology for about Rs 1,000-1,200 crore.

This is part of a broader strategy to reduce debt in the company’s capital structure after it borrowed more to help finance the Rs 4,600 crore acquisition.

Zydus Cadila has approached Cipla and Sun Pharmaceutical Industries, besides financial investors, such as Advent International, Blackstone, KKR and Carlyle. Investment bank Jefferies Group has been mandated to run a formal process to find a buyer.

The anti-infective division named Vivo sells under brands such as Ampilox, Biotax, Amicin, Monotax all acquired from Biochem Pharma in 2011. The gynaecology division Gynova sells brands such as Provironum, ZYHCG, Ovucet, and Ccliya drugs that treat infertility.

In January 2019, Zydus Wellness completed the Rs 4,600 crore acquisition of Heinz India's consumer wellness business, which included the Complan, Glucon-D, Nycil and Sampriti Ghee brands.

The acquisition included two large manufacturing facilities--one in Aligarh and another one in Sitarganj along with operations, research, sales, marketing and support teams, and a network of more than 800 distributors and 20,000 wholesalers in 29 states.

← All latest storiesBack to top →